Clinical Trial

ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial

Study aims to evaluate promising therapeutics that could slow or halt progression of Parkinson’s disease in prodromal patientsATLANTA and BOSTON,…

2 weeks ago

Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation

MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today…

2 weeks ago

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata regains full development rights to certepetide in the Greater China RegionBASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) --…

2 weeks ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial…

2 weeks ago

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the…

2 weeks ago

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million…

2 weeks ago

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM…

2 weeks ago

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage…

2 weeks ago

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated…

2 weeks ago

CancerIQ and Azra AI Partner to Support Growing Lung Cancer Screening Programs

Partnership aligns risk-based patient engagement, LDCT screening, and AI-powered imaging follow-up as lung programs scaleCHICAGO and NASHVILLE, Tenn., Jan. 26,…

2 weeks ago